Archive – Science

Ganymed closes substantial first round

This content was published on Jul 23, 2002 With Zurich’s Nextech Venture, an early stage oriented fund manager, as lead investor, the drug discovery firm was able to secure SFr12.9 million from an international syndicate of life science venture capital firms. The syndicate includes Süd Venture Capital Investition GmbH & Co.KG, Future Capital AG, Venture Incubator AG, the only other Swiss investor, the…

Happiness is: living in Switzerland

This content was published on Jul 23, 2002 Young or old, rich or poor, male or female, the Swiss are unanimous about one thing: happiness is a country called Switzerland. That’s the finding of a nationwide survey of 853 people, aged from 16 to 76, carried out last April. The results – presented at Switzerland’s national exhibition, Expo.02 – confirm what most Swiss…

Serono to develop new infertility treatment

This content was published on Jul 23, 2002 Under the agreement, the Geneva-based company will have the rights to develop, register and market the aromatase inhibitor, Anastrozole. The oral drug acts by blocking the synthesis of oestrogen, thereby improving ovulation. “We are very pleased to sign this agreement with AstraZeneca,” Serono said in a statement on Tuesday. “We believe Anastrozole can play a…

Quantum leap for uncrackable code

This content was published on Jul 23, 2002 id Quantique, a Geneva University spinoff, sent a totally safe message over the standard telephone network between Geneva and Lausanne – a record-breaking distance of 67 kilometres. The company uses quantum cryptography, a technique based on single photons of light, which allows users to tell if their data has been tampered with. The experiment suggests…

Swiss laser goes the last mile

This content was published on Jul 19, 2002 Most users have been unable to benefit from high speed access because of the so-called “last mile problem” – the need to dig up city streets to lay fibre-optic cables which can transmit billions of data bits every second. An alternative approach has been free-space optics, in which an infrared laser beams data to a…

Orders trickle in at Sulzer

This content was published on Jul 18, 2002 The group, which is based in Winterthur, said in a statement on Thursday that orders for the first six months were some three per cent down on last year’s figure, totalling SFr1.013 billion ($700 million). Order intake for the year as a whole is expected to match that of 2001. The company said that the…

Swiss link development aid to economic reform

This content was published on Jul 16, 2002 The new strategy will see the recipients of development aid cut from the current 50 countries to just 26. Martin Roth, head of development and transition in the economics ministry (Seco), said cutting the number of recipient countries was designed to “improve the management, the coherency, efficiency and impact” of Swiss development aid. Seco’s contribution…

Swiss pharma unmoved by Pfizer deal

This content was published on Jul 16, 2002 Daniel Vasella, head of the Swiss pharmaceutical giant, Novartis, said the group did not feel compelled to do a deal, and that no talks were underway with its rival, Roche, in which Novartis has a 21.3 per cent stake. “The only that happened is that Pfizer, who was number one, became a bigger number one.”…

Scientists secure funds for addiction firm

This content was published on Jul 15, 2002 The new company, Addex Pharmaceuticals, will focus on compounds for nicotine, alcohol and cocaine dependence. “Existing treatments don’t really cure the disease,” said Addex’s chief executive François Conquet, who headed the department of experimental pathology at Lausanne University. “If you want to quit smoking, you might have the option of a patch or chewing gum…

Novartis boss fuels Roche merger speculation

This content was published on Jul 11, 2002 In an interview with the German business magazine, “WirtschaftsWoche”, the chairman and chief executive of Novartis said there would be distinct advantages to both companies working together. “Roche and Novartis together would without a doubt be a great company,” Vasella commented. “There would be many synergies, we would have much more clout in marketing and…

Archive – Science

Popular Stories

Most Discussed

Archive – Science

More

Ganymed closes substantial first round

More

Happiness is: living in Switzerland

More

Serono to develop new infertility treatment

More

Quantum leap for uncrackable code

More

Swiss laser goes the last mile

More

Orders trickle in at Sulzer

More

Swiss link development aid to economic reform

More

Swiss pharma unmoved by Pfizer deal

More

Scientists secure funds for addiction firm

More

Novartis boss fuels Roche merger speculation

Popular Stories

Most Discussed